The DCVAC medicinal product
SOTIO is developing a new Active Cellular Immunotherapy medicinal product, entitled DCVAC/PCa, for prostate cancer patients, and DCVAC/OvCa, for epithelial ovarian cancer patients.
The possibility of combining immunotherapy treatment with current standard procedures produces synergic effects and has the potential to enhance the overall therapeutic effects. Unlike other chemotherapeutical combinations, DCVAC can be applied without difficulty and without increasing the toxicity of the concurrently-administered treatment. The testers have not registered any serious undesirable side-effects or reactions related to DCVAC application in the clinical trials conducted so far.
You can find more information about Active Cellular Immunotherapy of cancer diseases using dendritic cells in the Research section.
Manufacturing process for DCVAC
DCVAC is manufactured individually for each patient in SOTIO’s modern laboratories. The drug contains living dendritic cells activated by tumor antigens. Approximately 100 ml of blood with an increased leukocyte count, taken from patients using a special sampling method (leukapheresis) at blood transfusion sites, is used to prepare it. One sample is enough to produce 15 doses, enough for long-term drug administration over 12 to 18 months.
When the blood sample is processed in SOTIO’s laboratories, a suspension of leukocytes is obtained, from which immature dendritic cells are isolated. These dendritic cells are activated through incubation with dead tumor cells. As a result of this process, following their reinjection into the patient’s body, mature dendritic cells are able to activate the immune system and induce an immune reaction against the tumor cells.
Mature dendritic cells are an effective component of the drug being evaluated; at the end of the production process, it is frozen and stored at -196 °C. After thawing, the attending physician can easily administer the cells to patients using subcutaneous injections in the doctor’s surgery.